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Recent years have seen expanding opportunities to use electronic health and administrative data for efficient, 
real world studies to inform planning and innovations in clinical practice. Attracting inward investment is a 
further goal behind the UK government’s Strategy for UK Life Sciences, which has sanctioned huge investment 
in e-health and administrative data, including the Clinical Practice Research Datalink (£60m), the ESRC 
investment in Big Data (£64m), the creation of four UK e-health research centres (£39m), and a new Office for 
Life Sciences. This investment is also reflected within the EU more broadly (www.ehr4cr.eu)1.  
While opportunities for more efficient recruitment and follow-up in randomised controlled trials (RCTs) have 
been key drivers for greater use of e-health data, there is scope to add further value from combining trials with 
e-health data2, 3. We propose that e-health data has the potential to support and enhance RCTs in four main 
areas. 
Firstly, pre-trial study design and recruitment. The national coverage of e-health data can be exploited to 
identify potential patient cohorts, including those who are typically difficult to recruit into trials4. This could 
allow identification of complete populations of cases either through linkage with disease-specific registries 
(such as the UK Cystic Fibrosis Registry) or by capturing populations with rare conditions within e-health data, 
that it might otherwise be difficult to identify and recruit. These data sources could also be used to identify 
sub-populations who are most at risk and who could benefit most from evidence on potential new 
interventions, to aid site selection, and to establish potential study samples that reflect the mix of patients 
seen in practice. E-health data can also support robust, cost-effective and efficient feasibility studies, the 
importance of which is increasingly being recognised by funders5. Determining event rates and parameters to 
support sample size calculations, and identifying variation in care across services, will lead to more well-
designed trials that are likely to succeed.  
Secondly, outcomes and comparative effectiveness. E-health data may help to augment primary data 
collection by capturing information on clinical events, thereby preventing replication of labour-intensive data 
collection and greatly reducing the burden on research nurses. E-health data could completely replace 
outcome measurement in specific situations (but may not be approved in others e.g. clinical trials of 
investigational medicinal products)6. Linkage of longitudinal records belonging to the same individual allows 
different episodes and mortality records to be complied, providing comprehensive information on patient 
characteristics and previous medical history. This is particularly relevant for capturing long-term outcomes and 
safety measures that could not be collected during the trial (e.g. deaths, cancer outcomes, or educational 
outcomes)7. Additionally, e-health data could contribute to assembling core outcome sets (e.g. www.comet-
initiative.org).  
Thirdly, assessment of generalisability. The extent to which the results of a trial are relevant to a definable 
group of patients in a particular clinical setting can be determined through the use of e-health data. E-health 
data can be used to assess how trial results generalise to wider populations and to contextualise results by 
measuring changes over time in event rates in patients not in the trial. In addition, e-health data can be used 
to identify variation in care and outcomes across units, allowing targeted improvement and more rapid 
adoption of interventions for populations most likely to benefit (e.g. targeting infection prevention strategies 
at patient groups at high risk of infection).  Exploiting e-health data supports the efficient translation of 
evidence of effectiveness into practice.  
Fouthly, post-trial monitoring. E-health data can be used to monitor the scaling-up of interventions found to 
be effective in trial settings and to detect variation in the adoption of interventions. This would provide a cost-
effective approach for continued study of safety and efficacy of new medicines and devices after approval and 
also for monitoring shifts in practice for off-label treatments that are already in widespread use8.  
There are now some examples of e-health data being successfully used within or alongside RCTs. The CATCH 
trial (CATheters infections in CHildren) is using routinely-collected hospitalisations data (hospital episode 
statistics) for 6-month follow-up, and linkage between the national laboratory surveillance system and the 
Paediatric Intensive Care Audit Network (PICANet) for a generalisability study.  
However, challenges to realising the full potential for integrating e-health data into RCTs remain. There are 
concerns about the quality of data that has not been collected primarily for research, specifically relating to 
the completeness and accuracy with which particular conditions and interventions are coded, the types of 
outcomes that need to be recorded, and the representativeness of identified cohorts and events rates . 
Improving data quality may pose significant administrative burden. Regulatory compliance, including 
management of data queries, audit trails and adverse event reporting, can also be an issue. There are ethical 
considerations in accessing anonymised patient data for the purposes of trial design (e.g. for determining 
event rates and selecting sites) and contacting potential participants identified through e-health data. Recent 
investments are helping to address some of these issues through development of robust safeguards for 
confidential information, including data ‘Safe Havens’. The appropriateness of each of the four facets of e-
health infrastructure should therefore be considered on an individual study basis.  
Evidence shows that patients are supportive of the use of e-health data for health research, but appropriately 
simple consent models for the use of e-health data for these purposes still need to be developed9,10. This 
approach may be particularly useful where consent to the trial can be integrated into routine care, for example 
surgical procedures or insertion of catheters, as in the CATCH trial. The use of e-health data for RCTs could be 
further streamlined if research participation could be routinely recorded in administrative data. Such recording 
could be used to identify under- and over-investigated patient groups and allow monitoring of safety and 
hospitals that do not participate in research11. 
Using e-health data to support RCTs provides an opportunity to efficiently investigate short- and long-term 
effectiveness of medical interventions in real healthcare settings, and to assess the broader impact of 
treatments across entire health systems12. Ultimately, this has the potential to improve quality and decrease 
the burden and cost of RCTs, and provide evidence on interventions to help policy makers and practitioners 
implement improved healthcare treatments quickly for those who would benefit most. In order to unlock this 
potential in all countries where e-data is available, further research on the challenges and benefits of using e-
health data for supporting RCTs should be a priority.  
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